80653-80-1

Upstream product

• 40034-44-4 3-(pyridin-4-yl)benzenamine 
• 591-20-8 3-Bromophenol 
• 1692-15-5 4-pyridylboronic acid 
• 4373-68-6 4-(3-methoxyphenyl)-pyridine 

Downstream Products

• 4373-68-6 4-(3-methoxyphenyl)-pyridine 
• 1012886-82-6 4-(3'-hydroxyphenyl)-1-[2-(4-iodophenyl)-allyl]pyridinium bromide 
• 1012886-67-7 C₁₂H₁₂NO⁽¹⁺⁾*I^(1-) 
• 80653-85-6 2-amino-5-(pyridin-4-yl)phenol 

Relevant academic research and scientific papers

Cd(II)-MOF: Adsorption, separation, and guest-dependent luminescence for monohalobenzenes

A series of isostructural 2-fold interpenetrating 2D Cd(II)-MOFs, namely G?CdL2(OTs)2 (G = THF (1), PhF (2), PhCl (3), PhBr (4), PhI (5), L = 1,2-bis[(3-(pyridin-4-yl)phenoxy]ethane, and OTs- = p-toluenesulfonate anion), have been successfully synthesized from the flexible ethylene glycol ether-bridging ligand L and Cd(OTs)2 in solution. The CdL2(OTs)2 framework contains squarelike nonpolar channels, and the encapsulated guest molecules can be removed by heating (150°C) to generate a guest-free host framework which is able to reversibly adsorb monohalobenzenes PhX (X = F, Cl, Br, I) in the liquid phase under ambient conditions without loss of framework integrity. Furthermore, it can effectively separate these monohalobenzenes and exhibits a clear affinity for monohalobenzenes according to the following order: PhI > PhBr > PhCl > PhF. In addition, PhX?CdL2(OTs)2 exhibits guest-dependent luminescence properties.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Vesicular monoamine transporter substrate/inhibitor activity of MPTP/MPP+ derivatives: A structure-activity study

The active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), N-methyl-4-phenylpyridinium (MPP+), selectively destroys the dopaminergic neurons and induces the symptoms of Parkinson's disease. Inhibition of mitochondrial complex

2-Amino-3(4 or 5)-(pyridinyl)phenols and their use as cardiotonics

2-Amino-3(4 or 5)-PY-phenol, a cardiotonic agent, is prepared by reducing 2-nitro-3(4 or 5)-PY-phenol, where PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents. 2-Amino-3(4 or 5)-PY-phenol or pharmaceutically-acceptabl